Qiagen N: Liquid-Based Sample Preparation and Detection Kit Helps Labs Increase COVID Testing Capacity by Reducing Processing Times
- artus® SARS-CoV-2 Prep & Amp UM cuts PCR processing times by two-thirds
The kit reliably detects SARS-CoV-2 infections with the Omicron variant on all PCR instruments
QIAseq DIRECT SARS-CoV-2 Kit Enables Laboratories to Dramatically Increase Sequencing
Hilden, Germany, and Germantown, Maryland, January 13, 2022 – QIAGEN announced today that it is working with genetics labs around the world to increase COVID-19 testing capacity with its artus® SARS-CoV-2 Prep & Amp UM Kit which uses liquid-based sample preparation technology to reduce processing times for PCR results by up to two-thirds. The company has significantly increased its production capacities to be able to meet the growing demand for testing spurred by the emergence of the new Omicron variant.
Integrate sample preparation and detection in a single kit, artus® SARS-CoV-2 Prep & Amp UM enables laboratories to analyze samples in one hour – instead of the three hours typically required by real-time PCR processes based on standard extraction. The kit is compatible with all PCR machines and can support up to 672 samples analyzed by a thermal cycler in an eight hour shift.
“Since we started using this QIAGEN kit, we have been able to triple our PCR capacity to test for SARS-CoV-2,” said Ludwig Knabl, medical director of the Molecular Biology Laboratory at Tyrolpath Obrist Brunhuber GmbH. “artus® SARS-CoV-2 Prep & Amp UM is faster than standard processes and can detect the virus just as reliably, including the new Omicron variant. The kit’s simple workflow speeds up turnaround time and reduces the workload for our lab technicians. ”
QIAGEN artus® SARS-CoV-2 Prep & Amp UM Kit has been CE-IVD registered for clinical use in the European Union and other markets and is available for research in the United States. The kit combines liquid sample preparation – which takes no more than two minutes – with real-time PCR testing. It comes with all the reagents necessary for the sample-result test of samples. The test is validated for different types of swabs as well as for raw saliva in asymptomatic and symptomatic patient populations.
“Our artus SARS-COV-2 Prep & has gained ground in the market during times of high global test demand. Its new sample preparation technology enables laboratories to increase PCR testing capacity using their existing infrastructure – a crucial factor as the Omicron variant of SARS-CoV-2 spreads rapidly, “said Kai te Kaat, vice president, program manager, life sciences business area at QIAGEN.” After increasing dramatically our production capacity, we are convinced that we will be able to meet the growing demand from PCR laboratories. ”
QIAGEN is also helping laboratories develop a more complete picture of circulating SARS-CoV-2 variants by enabling them to dramatically increase genomic surveillance using next-generation sequencing (NGS). The new and improved QIAseq DIRECT SARS-CoV-2 kit modifies the existing workflow to provide higher coverage and uniformity and requires fewer sequencing reads, allowing researchers to identify and distinguish between several more quickly and easily. circulating variants of concern, (including the Omicron and Delta variants) even in samples with very low concentrations of SARS-CoV-2.
More information on artus® SARS-CoV-2 Prep & Amp UM Kit can be found here.
More information about the QIAseq DIRECT SARS-CoV-2 kit can be found here.
For an overview of QIAGEN’s coronavirus testing solutions, please visit http://www.qiagen.com/coronavirus.
QIAGEN NV, a Netherlands-based holding company, is the world’s leading provider of Sample to Insight solutions that enable customers to gain valuable molecular information from samples containing the building blocks of life. Our sampling technologies isolate and process DNA, RNA and proteins from blood, tissues and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to provide relevant and actionable information. Automation solutions link them together in transparent and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers worldwide in molecular diagnostics (human health), applied testing (mainly forensics), pharmacy (pharmaceutical and biotechnology companies) and academia (life science research ). As of December 31, 2020, QIAGEN employed more than 6,000 people in more than 35 locations around the world. More information is available at http://www.qiagen.com.
Certain statements in this press release may be deemed to be forward-looking statements within the meaning of Section 27A of the US Securities Act of 1933, as amended, and Section 21E of the US Securities Exchange Act of 1934, as amended. . To the extent any of the statements contained herein regarding QIAGEN’s products, collaborations, markets, strategy or results of operations, including, without limitation, its expected adjusted net sales and its results, adjusted for diluted earnings, are forward-looking; these statements are based on current expectations and assumptions which involve a number of uncertainties and risks. These uncertainties and risks include, but are not limited to, risks associated with managing growth and international operations (including the effects of currency fluctuations, regulatory processes and reliance on logistics), variability in operating results and allocations between customer categories; commercial development of markets for our products to academic, pharmaceutical, applied testing and molecular diagnostics customers; changing relationships with customers, suppliers and strategic partners; competetion; rapid or unexpected technological changes; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, level and timing of customer financing, budgets and other factors); our ability to obtain regulatory approval for our products; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; QIAGEN’s ability to identify and develop new products and to differentiate and protect our products from competitive products; market acceptance of new QIAGEN products and integration of acquired technologies and businesses. For more information, please refer to the discussions in the reports that QIAGEN has filed with, or provided to, the United States Securities and Exchange Commission (SEC).